Author

Alina Naveed

University of BernORCID 0000-0002-1820-9908Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Alden King-Yung LeungiD· 1 shared Andrej BenjakiD· 1 shared Bence DánieliD· 1 shared Charlotte K.Y. NgiD· 1 shared D. A. Quigley· 1 shared Giada Andrea CassanmagnagoiD· 1 shared Haiyuan YuiD· 1 shared Himisha BeltraniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alden King-Yung LeungORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

Phillip Thienger, Irene Paassen, Xiaosai Yao, Philip D. Rubin, Marika Lehner, Nicholas Lillis, Andrej Benjak, Sagar R Shah, Alden King-Yung Leung, Simone de Brot, Alina Naveed, Bence Dániel, Minyi Shi, Julien Tremblay, Joanna Triscott, , Mark A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

Cancer Research · Jan 14, 2026Peer-reviewedCancer Biology